SCHEDULE 13D/A: Major Sonim Technologies Shareholder Group Sues Board Over Director Nominations and Alleged Entrenchment

A significant shareholder group, including AJP Holding Company and Orbic North America, has filed a lawsuit against Sonim Technologies Inc. and its board, alleging breach of fiduciary duties and improper rejection of director nominations aimed at entrenching current management.

Summary

• AJP Holding Company, LLC and Orbic North America, LLC, along with associated individuals, who collectively beneficially own 30.7% of Sonim Technologies Inc. common stock, have filed a lawsuit against the company and certain board members.
• The lawsuit, filed on April 24, 2025, in the Delaware Court of Chancery, seeks to enjoin the board from preventing the plaintiffs from nominating directors and to find that the director defendants breached their fiduciary duties.
• Plaintiffs allege the board improperly rejected their nomination notice for five director candidates, claiming a bylaw violation based on a missing "conclusory sentence" despite extensive nominee qualifications provided.
• The lawsuit claims the board's actions, including the rejection of nominations and the adoption of a "Poison Pill" on April 21, 2025, are attempts to entrench current management.
• Plaintiffs highlight Sonim's "dismal" performance, including an approximately 99% stock price decline since February 2021, and recent annual losses of $33.6 million or $7.13 per share.
• The board is also accused of significantly increasing change of control severance payments for the CEO and CFO after the nomination notice and an acquisition offer were made.
• Orbic North America previously submitted a non-binding offer to acquire Sonim for $4.00 per share in cash on March 31, 2025, representing an 80% premium, which the Special Committee questioned and sought a higher price for.

Sentiment

Score: 2

Explanation: The document details a significant shareholder lawsuit against the company's board, alleging entrenchment, fiduciary duty breaches, and improper rejection of director nominations. It highlights a 99% stock price decline and substantial annual losses, indicating severe operational and governance issues. While an acquisition offer was made, the board's defensive actions and the ongoing litigation create high uncertainty and negative sentiment for the company's current state.

Positives

• Orbic North America, a significant shareholder, made a non-binding offer to acquire Sonim Technologies Inc. for $4.00 per share in cash, representing an approximately 80% premium over the closing price on March 28, 2025.
• Orbic stated its intent to invest in and support Sonim's overall business, aiming for renewed growth and financial strength, and had no intent to dispose of any material part of Sonim's business.

Negatives

• Sonim Technologies Inc. has experienced a continuous decline in stock price, with an approximately 99% decline from over $125 per share in February 2021 to $1.49.
• The company announced staggering annual losses of $33.6 million or $7.13 per share on March 31, 2025.
• The board is accused of improperly rejecting a valid director nomination notice from a significant shareholder group, allegedly for pretextual reasons to block alternative candidates.
• The board significantly increased change of control severance payments for CEO Peter Liu (to 150% of 12 months salary) and CFO Clay Crolius (including a guaranteed pro-rated bonus of not less than 20% of annual salary) after the nomination notice and acquisition offer.
• The board adopted a "Poison Pill" (rights plan) on April 21, 2025, triggered at 15.5% ownership, which plaintiffs allege is solely for entrenchment purposes.

Risks

• Litigation Risk: Sonim Technologies Inc. and certain board members are facing a lawsuit in the Delaware Court of Chancery, which could result in significant legal costs and adverse judgments.
• Corporate Governance Issues: Allegations of the board weaponizing bylaws for entrenchment, rejecting valid director nominations, and adopting a poison pill indicate potential corporate governance failures and conflicts of interest.
• Shareholder Discontent/Proxy Contest: A significant shareholder group (30.7% ownership) is actively challenging the board, indicating a high likelihood of a proxy contest at the upcoming 2025 Annual Meeting.
• Management Instability: The ongoing dispute and allegations against current management could lead to instability and distraction, impacting operational focus and strategic execution.
• Reputational Damage: The public nature of the lawsuit and allegations of entrenchment could damage the company's reputation among investors, customers, and employees.
• Uncertainty Regarding Future Direction: The dispute over board composition and potential acquisition offers creates uncertainty about the company's future strategic direction and leadership.

Future Outlook

The plaintiffs intend to pursue their lawsuit to ensure their director nominees are presented to Sonim stockholders at the 2025 Annual Meeting, aiming to restore the company to stability, profitability, and stockholder value creation. Orbic North America also expressed an intent to solicit proxies for the 2025 Annual Meeting and is considering all available options to take its acquisition case directly to Sonim stockholders if a friendly combination is not agreed upon.

Management Comments

• "The Director Defendants have lost sight of this principle and have chosen to impose conditions on Plaintiffs right to nominate candidates for elections to Sonims board of directors (the Board) that simply do not exist under any reasonable interpretation of the Companys bylaws."
• "The Director Defendants have improperly attempted to twist legitimate information mechanics in the advance notice bylaws into a tripwire, purely for entrenchment purposes (much like their decision to adopt a poison pill as discussed below)."
• "The Special Committee agree[d] that a business combination premised on delivering a compelling premium to Sonims stockholders is critical."
• "The Special Committee questioned whether Orbic could actually consummate [the] proposed offer and requested conditions to move forward with the parties discussions."
• "The Special Committee requested that Orbic increase [its] price to an amount in excess of $4.21 per share given that [it] proposed to acquire a controlling interest."
• "The Board identified just a single purported deficiency with respect to the Nomination Notice, and on that basis alone, prevented Plaintiffs from putting their nominees, who all have the type of professional experience that Sonim needs most now, for election to the Board up for election at the 2025 Annual Meeting."

Industry Context

Sonim Technologies specializes in rugged and durable mobile devices for demanding workplaces, including enterprise, first responder, and government sectors, and has expanded into connected devices for wireless internet access. The current dispute highlights challenges faced by technology companies with declining performance and activist shareholders seeking to drive change, often through board representation or acquisition.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Sonim's performance against global benchmarks.
• However, the stated 99% stock price decline and significant annual losses suggest performance well below industry standards for a healthy technology company.
• The plaintiffs' nominees' backgrounds, including extensive experience at companies like Qualcomm and Microsoft, suggest an attempt to bring in expertise from leading technology companies, implying a current lack of such expertise or performance at Sonim.

Management Changes

Corporate Governance

Legal Proceedings

• AJP Holding Company, LLC and Orbic North America, LLC filed a Verified Complaint in the Delaware Court of Chancery on April 24, 2025, against Sonim Technologies Inc. and certain members of its Board of Directors (Mike Mulica, Peter Liu, James Cassano, and Jack Steenstra).
• The lawsuit seeks to permanently enjoin the Issuer and its Board from preventing AJP and Orbic from exercising their rights to nominate directors in accordance with the Issuer's corporate bylaws.
• The lawsuit also seeks a finding that the Director Defendants breached their fiduciary duties.
• Plaintiffs allege the board improperly rejected their director nomination notice and adopted a "Poison Pill" for entrenchment purposes.

Stakeholder Impact

• Shareholders: Significant impact due to ongoing litigation, potential proxy contest, uncertainty regarding board composition and future strategic direction, and the board's defensive actions (poison pill, increased severance) potentially limiting value realization.
• Management/Employees: Potential for instability and distraction due to the legal dispute and shareholder activism. Increased severance for top executives might be a positive for them but a negative for shareholders.
• Customers/Suppliers: Potential for uncertainty regarding the company's long-term stability and strategic focus, which could impact relationships.
• Creditors: The company's significant losses and ongoing dispute could raise concerns about financial health and repayment ability.

Next Steps

• The lawsuit will proceed in the Delaware Court of Chancery, seeking judicial enforcement of shareholder rights.
• Plaintiffs expect the 2025 Annual Meeting to be held in mid-to-late June 2025, where they intend to present their nominees for election to the Board.
• Orbic North America intends to solicit proxies for the 2025 Annual Meeting.
• Plaintiffs await Sonim's response to their proposed confidentiality agreement regarding the Section 220 Demand for books and records.
• Orbic North America may consider all available options to take its acquisition case directly to Sonim stockholders if a friendly combination is not achieved.

Key Dates

Recommendation

Keywords

Sonim Technologies, SONM, Schedule 13D/A, Shareholder Activism, Corporate Governance, Director Nomination, Proxy Contest, Delaware Court of Chancery, Fiduciary Duty, Poison Pill, Rights Plan, Acquisition Offer, AJP Holding Company, Orbic North America, Jeffrey Wang, Peter Liu, SEC Filing, Litigation, Shareholder Rights, Entrenchment